Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$2.02 - $3.14 $47,589 - $73,975
23,559 New
23,559 $56,000
Q4 2022

Feb 14, 2023

BUY
$5.69 - $10.07 $135,422 - $239,666
23,800 New
23,800 $188,000
Q1 2020

May 15, 2020

SELL
$11.67 - $22.53 $122,955 - $237,376
-10,536 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$16.33 - $21.37 $172,052 - $225,154
10,536 New
10,536 $190,000
Q2 2018

Aug 14, 2018

SELL
$10.25 - $17.45 $200,900 - $342,020
-19,600 Closed
0 $0
Q1 2018

May 15, 2018

BUY
$9.1 - $13.7 $178,360 - $268,520
19,600 New
19,600 $217,000

Others Institutions Holding CHRS

About Coherus BioSciences, Inc.


  • Ticker CHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,724,600
  • Market Cap $81.6M
  • Description
  • Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...
More about CHRS
Track This Portfolio

Track Bayesian Capital Management, LP Portfolio

Follow Bayesian Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bayesian Capital Management, LP with notifications on news.